VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO MAP 2022 | The prognostic value of circulating ceramides in mCRPC

Carlo Cattrini, MD, University of Genoa, Genoa, Italy, discusses the clinical impact on the findings of the association between circulating ceramides and poor prognosis in patients with metastatic castration-resistant prostate cancer (mCRPC). This interview took place at the Molecular Analysis for Precision oncology (MAP) Congress 2022 in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter